We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

AbbVie Filed Patent Suits To Delay Competition, Court Told

Law360, Philadelphia (February 7, 2018, 6:40 PM EST) -- The patent lawsuits filed by AbbVie Inc. and Besins Healthcare Inc. over generic testosterone replacement treatments were “anti-competitive weapons” used to delay competition for the brand-name drug AndroGel, an attorney for the Federal Trade Commission said Wednesday while opening the bench trial in the agency’s antitrust suit in Pennsylvania federal court.

Those so-called weapons were sham litigation against Teva Pharmaceuticals USA Inc. and Perrigo Co. which reaped over $1 billion in ill-gotten monopoly profits for the brand-name drug makers, and deprived customers of lower-priced versions of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.